CFTR and Duchenne muscular dystrophy: Emerging revolutionary genome editing techniques like Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR-CAS9) are already considered for clinical trials to correct genetic disorders like β-thalassemia (372), cystic fibrosis transmembrane conductor receptor (CFTR) mutation (373), and Duchenne muscular dystrophy (374) (DMD).